Apyx MedicalAPYX
Recorded

Apyx Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration35 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2026 Earnings Conference Call. At this time, all lines are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star then 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci Advisors.

Jeremy FefferManaging Director

Please go ahead. Thank you and welcome everyone to our third quarter 2026 earnings call.

Jeremy FefferManaging Director

Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the risk factor section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website.

Jeremy FefferManaging Director

We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. Reconciliations of these non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer.

Charlie GoodwinPresident and CEO

Please go ahead. Thank you, Jeremy, and thank you all for joining us today.

Charlie GoodwinPresident and CEO

Per our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our third quarter 2026 financial results, along with our guidance for the full year 2026. We will then open the call for your questions. Let me begin with a review of a few key highlights from our third quarter 2026 performance. We delivered another quarter of strong year-over-year growth with total revenue of $14 million, an increase of 9% compared with the third quarter of 2025. Growth was driven primarily by sales of AYON in the U.S. and Renuvion outside the U.S., reflecting continued demand for our body contouring technologies.

Charlie GoodwinPresident and CEO

For the three and nine months ended September 30, 2026, our Surgical Aesthetics segment grew over 17% and 26%, respectively, as compared to the same periods last year. We are pleased by the progress we have made with AYON in the one year since its full commercial launch. During the time, we have continued to build awareness of the platform and demonstrate the value of bringing fat removal, closed-loop contouring, Renuvion tissue contraction, and electrosurgical capabilities together in one integrated system. We are building on a foundation with the broader commercial rollout of AYON's power liposuction capability, consistent with the plans we outlined last quarter. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon. We estimate approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON's appeal.

Charlie GoodwinPresident and CEO

Therefore, the recent clearance and commercial launch of power liposuction was a pivotal catalyst in driving AYON's adoption. While the rollout remains in the early stages, feedback from surgeons has been very positive. Power Lipo was designed directly into every AYON, and activation requires only a simple software update and the purchase of the handpiece and cannula. Clinicians can seamlessly deploy the full clinical AYON solution with no downtime. The legacy liposuction products on the market haven't moved the needle on safety and efficacy in two decades. The AYON system, designed by surgeons to specifically close these clinical gaps by embedding next-generation safety and workflow optimization into a single elegant system, we believe AYON establishes a new benchmark for surgical performance. It is uniquely positioned to be the global standard of care for plastic surgeons.

Charlie GoodwinPresident and CEO

Renuvion remains central to our strategy, both as a standalone system and as an integrated part of AYON. Its tissue contraction capability complements fat removal, helping surgeons address skin laxity that remain after liposuction or significant weight loss. Continued demand for AYON and Renuvion reflects the value surgeons see in having these complementary technologies available for their patients. Our commercial strategy is supported by our continued commitment to building clinical evidence. Last quarter, we discussed studies reporting higher patient satisfaction and lower rates of abdominoplasty and surgical revision with Renuvion plus liposuction compared with liposuction alone, as well as improvements in cellulite appearance and skin laxity following combined Avéli and Renuvion treatment. In September, we added to this evidence with a prospective study evaluating Renuvion's effect on biological markers associated with skin quality, published in Plastic and Reconstructive Surgery Global Open.

Charlie GoodwinPresident and CEO

The study enrolled seven patients undergoing facelift surgery, with six completing the six-month follow-up. Tissue analysis at the visit showed 30% greater elastin fiber density and 34% less inflammation in treated tissue compared to untreated control areas. All six patients reported improvements in skin quality and satisfaction with their outcomes. These findings add direct human tissue evidence supporting the improvements surgeons and patients have observed with Renuvion and reinforce the value of evaluating tissue quality alongside tissue contraction. We believe this is an important consideration in body contouring, where achieving the desired results depend not only on removing the fat, but also addressing the quality and laxity of the skin that remains. Looking ahead, the continued adoption of GLP-1 medications is reshaping the body contouring patient population and creating what we believe is a meaningful long-term opportunity for our business.

Charlie GoodwinPresident and CEO

While these therapies are helping a growing number of patients achieve substantial weight loss, many are left with loose or lax skin and residual areas of fat that they want to address. As these patients reach or approach their target weight, we believe many will seek procedures that address these concerns more comprehensively. By combining advanced fat removal with Renuvion's tissue contraction capabilities, AYON positions us to help surgeons meet these needs. Our focus remains on transitioning this opportunity into broader adoption through continued commercial execution. Before I turn the call over to Matt, I want to recognize the Apyx team. We have successfully achieved our product development, regulatory, and sales goals, all while maintaining strict cost discipline. To that end, I am pleased to report that on a cumulative trailing 12-month basis, the company has achieved positive EBITDA.

Charlie GoodwinPresident and CEO

Now I will turn the call over to Matt for a review of our third quarter 2026 financial results in more detail, along with our financial guidance for 2026.

Matt HillCFO

Thanks, Charlie. Before I get started, please note that all references to our third quarter financial results will be on a GAAP and a year-over-year basis unless noted otherwise. As Charlie mentioned, total revenue for the third quarter 2026 increased 9% to $14 million compared to $12.9 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 17% or $1.9 million to $13 million compared to $11.1 million for the prior year period. This growth was driven by sales of AYON, as we commenced our commercial launch in the third quarter of 2025 and increased sales of generators internationally. These increases were partially offset by decreases in domestic sales of standalone generators and sales of single-use handpieces globally.

Matt HillCFO

Turning to the OEM segment, sales decreased 41.5% or approximately $0.7 million to $1.1 million for the third quarter of 2026, compared to $1.8 million for the third quarter of 2025. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on Surgical Aesthetics, we expect OEM segment revenue will decrease for the year. Domestic revenue increased 4% year-over-year to $9.7 million, and international revenue increased 22% year-over-year to $4.3 million for the third quarter of 2026. Gross profit for the third quarter 2026 increased 9% to $9 million, compared with $8.3 million in the prior year period. Gross profit margin for the third quarter 2026 decreased to 64.2% compared to 64.4% in the prior year period.

Matt HillCFO

The decrease is primarily attributable to geographic mix, with international sales comprising a higher percentage of total sales, and product mix within both the Surgical Aesthetics and OEM segments. These decreases were partially offset by an increase due to mix between our segments, with Surgical Aesthetics comprising a higher percentage of total sales. Operating expenses increased to $9.6 million for the third quarter 2026, compared to $9.1 million for the prior year period. The increase was mostly driven by a $0.4 million increase in salaries and related costs, and a $0.2 million increase in selling, general, and administrative expenses, which was partially offset by a $0.2 million decrease in professional services. Loss from operations was $0.6 million, compared with a loss from operations of $0.8 million for the third quarter of 2025.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day